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Stem cells are a scientific field of interest due to their therapeutic potential. There are different groups, depending on the
differentiation state. We can find lonely stem cells, but generally they distribute in niches. Stem cells don’t survive forever. They
are affected for senescence. Cancer stem cells are best defined functionally, as a subpopulation of tumor cells that can enrich for
tumorigenic property and can regenerate heterogeneity of the original tumor. Circulating tumor cells are cells that have detached
from a primary tumor and circulate in the bloodstream. They may constitute seeds for subsequent growth of additional tumors
(metastasis) in different tissues. Advances in molecular imaging have allowed a deeper understanding of the in vivo behavior of
stem cells and have proven to be indispensable in preclinical and clinical studies. One of the first imagingmodalities for monitoring
pluripotent stem cells in vivo, magnetic resonance imaging (MRI) offers high spatial and temporal resolution to obtain detailed
morphological and functional information. Advantages of radioscintigraphic techniques include their picomolar sensitivity, good
tissue penetration, and translation to clinical applications. Radionuclide imaging is the sole direct labeling technique used thus far
in human studies, involving both autologous bone marrow derived and peripheral stem cells.
1. Stem Cells
Stem cells are a scientific field of interest mainly due to their
therapeutic potential.
The term of stem cells came up to us via histologists in the
nineteenth century, who introduced it as a general, abstract
term for cells specifically involved in repair or regeneration.
With the discovery in the 1950s that bone marrow cells
could reconstitute the hematopoietic systems of irradiated
individuals, themodern stem cell concept began to crystallize
around the experimental procedures of transplantation and
reconstitution [1, 2]. The definition for tissue stem cells
proposed by Potten and Loeffler was undifferentiated cells
(relative to a functional tissue), capable of proliferation and
production of a large number of differentiated functional
progeny; they have the ability of self-maintenance of their
population and for regeneration of the tissue after injury.
This means that stem cells are defined by virtue of their
functional attributes and not by an explicit directly observ-
able characteristic. This functional definition is relative to the
stem cell role linked to the functional tissue regeneration
feature. But this definition doesn’t give us any characteristic
to identify morphologically the stemness [3].
Another point is the fact that it is assumed that stem
cells are undifferenctiated and they come from the earlier
stages of the development, This means, in a tissue, we can
find various types of stem cells, or a stem cell at different
points of maturation. (so, gives a possible way to classify
descendent transit and mature cells). Most over could be that
there are specific differentiation markers which would enable
a distinction of stem cells in relation to each other and in
relation to the functional cells they are eventually producing.
Flexibility is a key aspect we should include in the
definition of stem cells. It may be possible for a stem cell to
cease proliferation, that is, become quiescent, in which case
it does not act as an actual stem cell, but since it can reenter
the cycle it has the potential to act as a stem cell. Likewise
a transit cell may not normally self-maintain, but may do so
under special circumstances, thereby representing a potential
stem cell. The recent discovery that stem cell behaviors can
be acquired by ordinary cells following the introduction of a
small number of genes has intensified its interest.
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Figure 1: Stem cell niche. C-kit-positive stem cell in the center,
surrounded by supporting cells.
With this background, all the stem cells are the same
type of cell, but as we refer before there are different groups
of them depending on the differentiation state; in this
sense the three main groups included: toti or pluripotents,
multipotents, and commitment cells. The first group are
embryonic cells who have the ability to create any kind of
tissue. Second group are cells more differentiated, still stem
cells, which can create any kind of tissue derived from one of
the embrionary layers, endoderm, mesoderm, or ectoderm,
for example, mesenchymal stem cells (MSCs). Finally the
third group are those who can generate two or more lineages
in a tissue, for example, cardiac stem cells (CSCs) [4].
Focusing on adult stem cells, as we referred before, they
distribute in the different adult tissues, but it’s very curious
they don’t have an aleatory distribution. In fact they use
to localize in the most protect areas of the tissue, that is,
in heart; they are more abundant in the atria and in the
apex, the two localizations were the pressure that supports
the tissue is minor or in the ventricular area in nervous
system. We can find lonely stem cells, but generally they
distribute in niches (Figure 1). We define a niche like type
of cells and extracellular substrates that can indefinitely
house one or more stem cells (SCs) and control their self-
reproduction and production of their progeny in vivo. So
this means they are specific anatomic locations that regulate
how they participate in tissue generation, maintenance,
and repair. The niche saves stem cells from depletion,
while protecting the host from overexuberant stem cell
proliferation. It constitutes a basic unit of tissue physiology,
integrating signals that mediate the balanced response of
stem cells to the needs of organisms. The simple location
of stem cells is not sufficient to define a niche. The niche
must have both anatomic and functional dimensions. So
functions of niches included: spatial organization, filtration
of signals (proliferative, apoptotic . . .), provided supporting
cells, specific unions like cadherins, and determined type
division (symmetric or asymmetric) [5].
The niche may also induce pathologies by imposing
aberrant function on stem cells or other targets. The







Figure 2: Schema of types division in a stem cell.
dynamic system necessary for sustaining tissues and for the
ultimate design of stem cell therapeutics.
An important aspect of the niche is that determining type
division of the stem cells. These cells are very special in this
aspect too, because usually when a cell enters in cell cycle
producing two daughter cells similar to it. In the case of stem
cells this can change, so there are two options as follows.
(i) Symmetrical division: the cell gives two daughter
cells similar to her, like a regular cell type or two
commitment cells.
(ii) Asymmetrical: as the result of a stem cell division we
will get two different daughter cells, one similar to the
mother and another one that is a commitment cell, so
she will be a mature cell (Figure 2).
Once again the regulator of this cellular function is the
niche, and this receives the name hypothesis of the free niche.
This hypothesis tells us that if there is space for only one stem
cell more in the niche, the division will be asymmetrical, but
if there is space for two, the division will be symmetrical.
Symmetrical division is more frequent in embrionary period
and asymmetrical in cellular turnover.
Two proteins are implicated defining the type of division:
numb and α-adaptin. When the proteins are homogenously
distributed in the cell, the division will be symmetrical;
instead if protein concentrates in one cellular extreme,
division will be asymmetrical [6].
Contrary to what is thought stem cells don’t survive
forever. They are affected for senescence too, as demonstrated
by the Anversa’s work [7, 8]. Telomerase shortening, increase
in ROS products, and increase in levels of p53, p16 and p66
were demonstrated in stem cells, all of them shared facts with
senescent cells.
Many efforts are being made in the study of the mech-
anism implicated in stem cells, with therapeutic purposes.
Fields like degenerative lesions, tisular necrosis, had all their
witness in the application of stem cells. In fact, there are
several clinical trials focusing on the substitutive therapy
with stem cells, in cardiology, neurology, and orthopedic, but
still the results are not as good as researchers and clinicians
expect.
2. Cancer Stem Cells
Recently new discovers can be applied to the stem cells
knowledge in the oncology field. Nowadays the theory of the
origin of the tumors is in the stem cells is more and more
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Figure 3: Schema of the theoretical behavior of the stem cells
in cancer, its maintenance and transformation to produce distant
metastasis.
accepted, and every day there are more researchers focusing
their efforts implicated in this aspect.
Cancer stem cells (CaSCs) is best defined functionally, as
a subpopulation of tumor cells that can enrich for tumori-
genic property and can regenerate the heterogeneity of the
original tumor in immunocompromised mice. The existence
of CaSCs was hypothesized in the 60
′
s, and experimentally
isolated in the last decades, first in acute myeloid leukemia
and later in solid cancers, such as, breast cancer. Impor-
tantly, CaSCs were shown to be resistant to conventional
therapies, such as, chemotherapy and radiation. Therefore,
the prospective isolation, molecular characterization, and
therapeutic targeting of CaSCs in cancer will possibly mark
major advances in understanding their pathogenesis.
At the same time, the finding that only a small fraction of
the cells within malignant tumors can initiate new tumors
upon transplantation has led many cancer biologists to
embrace the notion that stem cells are the driving force
behind malignancies and to advocate redirecting cancer
therapy toward controlling or eradicating stem cells. Clearly,
we live in an era of biology when ideas and theories about
stem cells are a major part of the intellectual landscape [9].
The hypothesis of cancer is a stem cell disease includes
that in a tumour we have, at least, two types of cell
population: adult tumour cells and stem cell like, as well as
in normal tissue. It has been suggested that cancer is due to
an alteration in the normal homeostasis of stem cells. The
abundance of cancer stem cells is derived for their symmetric
division, and this would be the point to eradicate for
cancer treatment. The tumor stem cell hypothesis indicates
that this type of cell has all the characteristics of the
stem cell: capability of self-renewal, unlimited proliferation
potential, multiline differentiation, formation of new adult
cells, and asymmetric division, and they are originated of the
formation of metastasis, meaning that all the adult tumor
cells are coming from this kind of cell (Figure 3). For these
properties they are called initiating tumor cells too, and
probably, are the responsible for tumors refractoriness and
recurrence.
3. Circulating Tumor Cells
Another concept is the circulating tumor cells (CTCs) that
are cells that have detached from a primary tumor and
circulate in the bloodstream. CTCs may constitute seeds
for subsequent growth of additional tumors (metastasis) in
different tissues [10].
Cells capable of metastasis also acquire the ability
to invade another tissue [11]. For epithelial cancers this
involves cells undergoing an Epithelial-Mesenchymal Tran-
sition (EMT). EMT involves epithelial cells losing their
epithelial characteristics and acquiring a more mesenchymal
phenotype which occurs as a result of cytoskeletal changes
within the cells. These changes allow the cell to acquire a
more migratory phenotype [10, 12], increasing the probabil-
ity of tumour cells entering the blood and lymphatic systems.
This process is influenced by chemokines and their receptors
which are thought to play an important role in tumour devel-
opment by influencing tumour transformation, survival,
proliferation, invasion, and metastasis and also regulation
of angiogenesis and tumour-leukocyte interactions. Despite
this, the majority of circulating tumour cells appear to be
destroyed [11]. Those that persist may acquire the ability to
metastasize and once inside the target organ may undergo
Mesenchymal-Epithelial Transition (MET), proliferate and
if the environment is conducive the disseminated cells
may grow to establish a new tumour thus completing the
metastatic process [13].
First evidence indicates that CTCs markers applied in
human medicine are conserved in other species. Five of the
more common markers including CK19 are also useful to
detect CTCs in the blood of dogs with malignant mammary
tumors [14].
Standard procedure for isolating circulating stem cells
(CTCs) involves cell sorting of a subpopulation on the basis
of cell surface markers. Many of these surface markers have
been reported as present in the CaSC. These markers change
depending on the organ we are considering.
The detection of CTCs may have important prognostic
and therapeutic implications but because their numbers
can be very small, these cells are not easily detected [15].
Circulating tumor cells are found in different frequencies
per mL of whole blood in patients with metastatic disease.
To date, a variety of research methods have been developed
to isolate and enumerate CTCs [16]. The only USA Food
and Drug Administration (FDA) cleared methodology for
enumeration of CTCs in whole blood is the CellSearch
system. Extensive clinical testing done using this method
shows that presence of CTCs is a strong prognostic factor for
overall survival in patients with metastatic breast, colorectal,
or prostate cancer.
Morphological appearance is judged by human operators
and is therefore subjected to large interoperator variation
[17]. Several CTCs enumeration methods exist which use
morphological appearance to identify CTCs, which may also
apply different morphological criteria. A study in prostate
cancer showed that many differentmorphological definitions
of circulating tumor cells have similar prognostic value,
even though the absolute number of cells found in patients
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and normal donors varied by more than a decade between
different morphological definitions [18].
The behavior of the cells in cancer and metastasis
developing will be better known if we will be able to follow
these cells.
4. Stem Cells Imaging: MRI and Radionuclide
Imaging (PET and SPECT)
Over the last decade, advances in molecular imaging have
allowed a deeper understanding of the in vivo behavior of
stem cells and have proven to be indispensable in preclinical
and clinical studies.
There are two main classes of molecular imaging
techniques: direct cell labeling and reporter-gene imaging
(Figure 4). The former employs contrast agents, such as,
magnetic particles, luminescent nanoparticles, or radionu-
clides to directly label the cell, whereas the latter genetically
alters the cell to transcribe and translate a reporter protein.
While direct labeling is both straightforward to implement
and is commonly used, the contrast signal is diluted with
each cellular division and the technique cannot distinguish
viable cells from dead cells [19]. Reporter genes, on the
other hand, are only expressed by live cells and the signal
is propagated by daughter cells [20]. However, reporter
gene imaging requires transfection of genetic material using
plasmids, retroviral, or viral vectors, which raises the concern
of insertional mutagenesis and may necessitate the use of
apoptosis-inducing “suicide genes” before possible future use
in the clinic [21, 22].
5. MRI
As one of the first imaging modalities for monitoring
pluripotent stem cells in vivo, magnetic resonance imag-
ing (MRI) offers high spatial and temporal resolution to
obtain detailed morphological and functional information.
It requires the uptake of a contrast agent by the stem cell,
the most common of which are superparamagnetic iron
oxide (SPIO) nanoparticles. SPIOs can induce changes in T2
relaxivity at nanomolar concentrations [23, 24]. There are
twomainmethods by which stem cells can be directly labeled
by SPIOs. One method is magneto operation which involves
the coating of anionic SPIOs with cationic transfection
agents, such as, protamine sulfate or poly-L-lysine [25].
Stem cells subsequently endocytose the resulting complex
during incubation for around 24–48 hours [26]. Although
many studies have shown that magneto oporation does not
affect cell viability or function at low doses [26–28], there is
evidence that high doses can inhibit mesenchymal stem cell
(MSC) migration and colony formation ability [29].
Several groups have shown the use of SPIOs for non-
invasive MRI of neural stem cell migration, engraftment,
and morphological differentiation [30, 31]. The contrast
signals in these studies were detected for up to six weeks
and the stem cells retained the ability to proliferate and
differentiate. Other groups have shown that MRI can be used
to track mesenchymal stem cells (MSCs) in cardiac repair
after myocardial infarction [32]. Here the signals could be
detected long term for three to eight weeks. However, one
disadvantage inherent to both SPIO-labelingmethods is their
inability to distinguish viable cells from dead cells or from
scavenging macrophages.
6. PET and SPECT
The advantages of radioscintigraphic techniques include
their picomolar sensitivity, good tissue penetration, and
translation to clinical applications [19]. In fact, radionuclide
imaging is the sole direct labeling technique used thus far
in human studies, involving both autologous bone marrow-
derived stem cells [33] and peripheral hematopoietic stem
cells [34–36].
There are two main techniques for radionuclide imaging:
positron emission tomography (PET) and single photon
emission computed tomography (SPECT). SPECT tracers
directly emit a gamma ray in one direction, in contrast
to PET tracers, which send two gamma rays in opposite
directions and thus possess coincidence detection with a
higher spatial resolution. However, SPECT is generally less
expensive due to its longer-lived and more readily available
radioisotopes.
The most widely used PET isotopes are fluorine-18
(18F), which has a half life of 110 minutes. Copper-64
(64Cu) has a much longer half life of 12.7 hours [37].
64Cu can offer a longer duration of in vivo visualization of
stem cell behavior. 64Cu can also be bound to a lipophilic
redox-active carrier molecule, pyruvaldehydebis(N4-
methylthiosemicarbazone)(PTSM). 64Cu-PTSM has been
used to image hESCs differentiated towards renal lineages
in fetal rhesus monkeys [38] and has been shown to lack
adverse cellular effects [39].
The most widely used SPECT radionuclides are indium-
111 (111In), with a half life of 67 hours and the metastable
Technetium-99m (99mTc), with a half-life of 6 hours. While
111In provides a longer time window for cell imaging, 99mTc
can be used in higher doses to improve short-term imaging
resolution. Several groups have used 111In to image in vivo
trafficking and biodistribution of MSCs around sites of
myocardial injury in the canine [40, 41] and porcine animal
models [42]. Human clinical studies have also used 111In-
oxine [35, 43, 44] to assess stem cell trafficking in acute and
chronic myocardial infarction.
Although both PET and SPECT offer great sensitivity,
there are several disadvantages to both techniques, including
the leakage of radionuclides into nontarget cells [45], limited
time window for imaging due to half-life decay, lower
spatial resolution as compared to MRI, and the emission of
ionizing radiation that may impair stem cell proliferation
and survival.
Pluripotent stem cells share many properties in common
with cancer cells, including self-renewal, rapid proliferation,
lack of contact inhibition, and high telomerase activity
[46, 47]. Furthermore, cellular manipulations, such as, the
reprogramming of somatic cells into induced pluripotent
stem cells (iPSCs), transfection of reporter genes, and










Figure 4: Molecular imaging techniques: direct stem cell labeling and reporter-gene imaging.
overexpression of survival genes, can have unintended
tumorigenic side effects. Teratoma formation is another
concern, along with its potential to degenerate into malig-
nant teratocarcinomas [46]. Given these risks, understanding
stem cell tumorigenicity is of paramount importance for
future clinical applications.
One study using a double fusion reporter containing
enzyme firefly luciferase (Fluc) and GFP showed that
teratoma formation is dependent upon cell number. Assessed
over a period of eight weeks, a minimum of 1 × 105
intramyocardially injected hESCs were required to form
teratomas in mice [48]. Furthermore, a lower threshold of
1 × 104 cells following hind limb injection was required
to form teratomas, providing insight into niche dependency
[49]. Since angiogenesis is known to play a major role in
tumor growth and development, it is important to investigate
not only the tumor itself but also its supporting stroma. One
study used sodium iodide symporter (NIS) reporter imaging
to show that MSCs actively home in on growing tumors,
where they differentiate into vasculature and supporting
structures [50]. The upregulation of αvβ3 integrin is also
known to play a role in tumor angiogenesis. One study used
direct PET imaging with 64Cu-DOTA-RGD4 to target αvβ3
integrin, which successfully visualized in vivo hESC teratoma
formation in the mouse model. These findings show that
integrins play a major role in teratoma formation and angio-
genesis. Moreover, PET imaging may have promising clin-
ical applicability for monitoring tumorigenicity in humans
because BLI lacks the ability to penetrate deep tissues.
Due to the risks of teratoma formation, having a reporter
gene that serves as both an imaging modality as well as a
failsafe suicide switch would be highly desirable. One study
used HSV1-tk PET reporter imaging to selectively destroy
emerging teratomas with the administration of ganciclovir.
Future directions for mitigating the risks of tumorigenicity
include not only the use of reporter-suicide genes, but also
vector-and transgene-free reprogramming of somatic cells
into iPSCs and long-term multimodality imaging capable of
observing both emerging tumor cells and their supporting
stroma.
Although a great deal of information is already known
about the survival, biodistribution, tumorigenicity, and
immunogenicity of pluripotent stem cells, significant gaps
in knowledge remain. Molecular imaging will continue to
play a pivotal role in answering crucial questions about
clinical applications as well as in helping us understand the
underlying mechanisms of stem cell biology.
In fact, a new imaging agent, radio-labelled hedgehog,
detects cancer stem cells, potentially allowing for imaging
of “stem cell-like” cancer cells by positron emission tomog-
raphy (PET) in patients with breast cancer, according to
results of a pilot study, presented at the American Association
for Cancer Research 101st Annual Meeting 2010. Jennifer
Sims-Mourtada, Ph.D., Director of molecular research and
development at RadioMedix, Inc., Houston, Texas and
colleagues tested the ability to detect breast cancer stem-cell-
like populations using a protein, sonic hedgehog that was
radiolabeled with the positron emitting isotope gallium-68.
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Increased activation of the hedgehog pathway is observed
in cancer stem cells and aggressive tumours. Binding of the
radio-labelled hedgehog to the patched-1 hedgehog receptor
on the surface of breast cancer cells occurred, suggesting
potential for molecular imaging of breast cancer by PET.
A significant increase in binding was observed in cultures
enriched for breast cancer stem-like cells.
7. Conclusions
More in vivo molecular imaging studies must be conducted
to confirm long-term survival of these cells. The safety of
stem cell therapy in terms of tumorigenicity and immune
rejection must also be thoroughly examined. To that end,
molecular imaging studies capable of evaluating the risk of
cancer formation long-term or assessingmethods of immune
suppression for viable engraftment are highly valuable.
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